Literature DB >> 12850996

Is retroviral gene marking too dangerous to use?

M K Brenner1, H E Heslop.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 12850996     DOI: 10.1080/14653240310001307

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


× No keyword cloud information.
  8 in total

Review 1.  Designing T cells for cancer immunotherapy.

Authors:  Leslie E Huye; Gianpietro Dotti
Journal:  Discov Med       Date:  2010-04       Impact factor: 2.970

2.  Simplified process for the production of anti-CD19-CAR-engineered T cells.

Authors:  Barbara Tumaini; Daniel W Lee; Tasha Lin; Luciano Castiello; David F Stroncek; Crystal Mackall; Alan Wayne; Marianna Sabatino
Journal:  Cytotherapy       Date:  2013-08-28       Impact factor: 5.414

Review 3.  Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.

Authors:  X Wang; I Rivière
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

Review 4.  Biosafety features of lentiviral vectors.

Authors:  Axel Schambach; Daniela Zychlinski; Birgitta Ehrnstroem; Christopher Baum
Journal:  Hum Gene Ther       Date:  2013-02       Impact factor: 5.695

Review 5.  Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".

Authors:  Gianpietro Dotti; Barbara Savoldo; Malcolm Brenner
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

Review 6.  Immunotherapy of human cancers using gene modified T lymphocytes.

Authors:  Juan F Vera; Malcolm K Brenner; Gianpietro Dotti
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

7.  Identification of parameters required for efficient lentiviral vector transduction and engraftment of human cord blood CD34(+) NOD/SCID-repopulating cells.

Authors:  Ying Liu; Giao Hangoc; Timothy B Campbell; Michael Goodman; Wen Tao; Karen Pollok; Edward F Srour; Hal E Broxmeyer
Journal:  Exp Hematol       Date:  2008-08       Impact factor: 3.084

Review 8.  Clinical manufacturing of CAR T cells: foundation of a promising therapy.

Authors:  Xiuyan Wang; Isabelle Rivière
Journal:  Mol Ther Oncolytics       Date:  2016-06-15       Impact factor: 7.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.